Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Switch Clear all
Terminated Phase 4 Interventional Results available

Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia

NCT01929889
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Iloperidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 18, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

NCT03485950
View directory record Official record
Conditions
Other Infectious Diseases
Interventions
Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 18, 2026, 6:31 PM EDT
Completed Phase 3 Interventional Results available

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

NCT00460746
View directory record Official record
Conditions
HIV
Interventions
TMC125, Darunavir; Ritonavir
Drug
Lead sponsor
Tibotec, Inc
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 18, 2026, 6:31 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

NCT00401973
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorders
Interventions
olanzapine, amantadine, metformin, zonisamide, Wellness education
Drug · Behavioral
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
National City, California • Canton, Ohio • Johnson City, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2009 · Synced Oct 18, 2026, 6:31 PM EDT
Completed No phase listed Observational

SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

NCT00225082
View directory record Official record
Conditions
HIV Infection
Interventions
Nucleoside analogue switch
Drug
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Oct 18, 2026, 6:31 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)

NCT04240210
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Symtuza
Drug
Lead sponsor
Midland Research Group, Inc.
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Oakland Park, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 18, 2026, 6:31 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Activity Tracking, Care Partner Co-participation, Text Reminders, Instructional Education, Video-Guided Physical Rehabilitation, and Exercise

NCT07321587
View directory record Official record
Conditions
Mild Dementia
Interventions
ACTIVE Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 18, 2026, 6:31 PM EDT
Completed Phase 3 Interventional Results available

Switch to Maraviroc + Integrase Inhibitor

NCT01896921
View directory record Official record
Conditions
HIV
Interventions
Switch to Maraviroc + Raltegravir or Dolutegravir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 18, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis

NCT01806662
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ustekinumab, Placebo
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 18, 2026, 6:31 PM EDT
Recruiting Phase 1Phase 2 Interventional

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

NCT07276373
View directory record Official record
Conditions
Neoplasms
Interventions
Nenocorilant 200 mg, Nenocorilant 300 mg, Nenocorilant 400 mg, Nivolumab
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 18, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3041658 in Adults With Hidradenitis Suppurativa

NCT04493502
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Placebo, LY3041658
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Rogers, Arkansas • Fountain Valley, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 18, 2026, 6:31 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

NCT03578367
View directory record Official record
Conditions
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic, Hematologic Diseases
Interventions
Asciminib add-on, Imatinib, Nilotinib, Asciminib 80mg QD (asciminib single agent (ASAC))
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Augusta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 18, 2026, 6:31 PM EDT
Active, not recruiting Phase 3 Interventional

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
64
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 18, 2026, 6:31 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

NCT06544733
View directory record Official record
Conditions
HIV-1-Infection
Interventions
Lepetegravir, Lenacapavir pacfosacil, Placebo to Match BVY, Bictegravir/emtricitabine/tenofovir alafenamide, Lepetegravir/Lenacapavir pacfosacil FDC, Placebo to Match GS1720/GS-4182 FDC
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
35
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 18, 2026, 6:31 PM EDT
Completed Phase 4 Interventional Results available

Switching to Iloperidone From Other Antipsychotics in Schizophrenia

NCT01207414
View directory record Official record
Conditions
Schizophrenia
Interventions
iloperidone
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 64 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
59
States / cities
Birmingham, Alabama • Cerritos, California • Costa Mesa, California + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 18, 2026, 6:31 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 18, 2026, 6:31 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

NCT07416526
View directory record Official record
Conditions
Hemophilia A
Interventions
NXT007, Human Coagulation Factor VIII
Combination Product · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Aurora, Colorado • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 18, 2026, 6:31 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

NCT05630755
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 18, 2026, 6:31 PM EDT
Completed Phase 2 Interventional

Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads

NCT00036465
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment regimen change
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
23
States / cities
Menlo Park, California • Stanford, California • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Oct 18, 2026, 6:31 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)

NCT02990806
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
NI-071, Remicade
Drug
Lead sponsor
Nichi-Iko Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
75
States / cities
Little Rock, Arkansas • Los Angeles, California • Ventura, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 18, 2026, 6:31 PM EDT
Completed Phase 1 Interventional

Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression

NCT00787501
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SSRI, CBT
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 18, 2026, 6:31 PM EDT
Terminated Not applicable Interventional Results available

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

NCT00726830
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Spartanburg, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 18, 2026, 6:31 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

NCT02030600
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
161
States / cities
Birmingham, Alabama • Haleyville, Alabama • Montgomery, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 18, 2026, 6:31 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Alternate Nicotine Delivery Systems and Airway Epithelial Biology

NCT01974063
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 18, 2026, 6:31 PM EDT